HVTN 084 – Injectable HIV drug prevents infections

The IAS hosted Global HIV Vaccine Enterprise welcomes interim results showing effectiveness of long-acting injectable PrEP. New results announced today by ViiV healthcare show that injection of long-acting pre-exposure prophylaxis (PrEP) cabotegravir every two months is 89% more effective than a daily Truvada oral pill in a trial of women at increased risk of HIV acquisition.

HIV Vaccine Roadmap at AIDS 2020 Virtual!

With over 600 virtual sessions and events, AIDS 2020: Virtual will enable delegates to access and engage with the latest HIV science, advocacy and knowledge traditionally presented at the conference, while offering a range of new features made possible by the new virtual format. Biomedical prevention interventions have saved lives and helped prevent new HIV infections. However, declines in incidence remain far from UNAIDS targets. A safe and globally effective HIV vaccine remains a necessity for a durable control and end to the epidemic. Download the HIV vaccine, and vaccine research roadmap.

What years of HIV vaccine research can teach us about the search for a COVID-19 vaccine

SARS-CoV-2, the virus that causes COVID-19, has taken the world by surprise, just as HIV did in the 1980’s. However, unlike HIV, the world has come together and shown that a coordinated, global response to a pandemic is possible in record time. Many aspects of this response, including the search for a vaccine, have built upon technologies and lessons learned from recent epidemics, including HIV.